Sanofi's Zerhouni at the EMA: More collaboration and fewer specialty medicines please
This article was originally published in Scrip
Executive Summary
The pooling of knowledge, collaboration rather than confrontation, stratified benefit-risk assessments, adaptive pathways, and the appliance of science to improve drug regulation. These are some of the key elements of Elias Zerhouni's vision of the future – or at least the future he'd like to see.
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.